Conformis to Present at the Canaccord Genuity Musculoskeletal Conference
Bedford, Mass. – March 5, 2014 – Conformis, Inc., a medical device company pioneering patient-specific orthopedic implants, will present at the Canaccord Genuity Musculoskeletal Conference in New Orleans, LA. Dr. Philipp Lang, Chairman and CEO of Conformis, will provide an update on the company’s proprietary technology for patient-specific implants and instruments, including its unique Digitally Driven Just-In-Time (JIT) delivery model and novel, innovative, 3-D additive printing technologies. Dr. Lang’s presentation will begin at 8:40 AM (CDT) on Tuesday, March 11, 2014.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary technology is supported by more than 375 patents and patent applications. Conformis’ award winning partial and total knee replacement solutions, the iUni® G2, iDuo® G2 and iTotal® G2, are individually designed for each patient. Potential advantages compared to traditional off-the-shelf implants include faster recovery, shorter hospital stay, less blood loss, more bone preservation, and better functional outcomes. Conformis products are provided in a pre-sterilized single package delivery system that can help hospitals reduce costs and treat more patients by reducing instrument re-sterilization costs and shortening set-up, procedure and turnover times. The iUni® G2, iDuo® G2 and iTotal® G2, have been cleared by the U.S. FDA and are CE Marked in Europe.
Conformis is the leader in additive manufacturing in the orthopedic and medical device space. Conformis is the only orthopedic company that offers Just-In-Time (JIT) manufacturing with a single-package delivery system, resulting in greatly enhanced use of working capital.
Conformis technology is broadly applicable to all joints. The company is expanding into new applications and indications.
For more information visit www.conformis.com, follow @Conformis on Twitter, or ‘Like’ the Conformis Facebook page.
